A Study of Bomedemstat (MK-3543) in Participants With Mild or Moderate Hepatic Impairment (MK-3543-023)

Inclusion criteria

The main inclusion criteria include but are not limited to the following:

• Is a non-smoker or is a moderate smoker for at least 3 months prior to dosing

Participants with Mild and Moderate HI

• Is classified as having either mild HI (Group 1) or moderate HI (Group 2) score on the Child-Pugh scale ranging from 5 to 6 (mild) or 7 to 9 (moderate)
• Has a diagnosis of chronic (> 6 months), stable (no acute episodes of illness within the previous 2 months due to deterioration in hepatic function) hepatic insufficiency with features of cirrhosis due to any etiology

Healthy Control Participants:

• Must match the mean age (± 15 years) of participants with mild HI and moderate HI
• Must match the mean body-mass index (BMI) (± 25%) of participants with mild HI (Group 1) and moderate HI
• Must match the sex ratio (±2) of participants in each HI group, separately

Exclusion criteria

The main exclusion criteria include but are not limited to the following:

All Participants

• History of cancer (malignancy)
• Female participants of childbearing potential
• Is positive for Hepatitis C virus (HCV)
• Is positive for Hepatitis B surface antigen (HBsAg)
• Is positive for human immunodeficiency virus (HIV)

Participants with Mild and Moderate HI

• Has any significant arrhythmia or conduction abnormality
• Severe complications of liver disease within the preceding 3 months
• Primary biliary cholangitis or biliary obstruction
• Has a history of a recent variceal bleeds
• Has evidence of hepatorenal syndrome
• Has a history of liver or other solid organ transplantation
• Has an active infection requiring systemic therapy
• Requires paracentesis more often than 2 times per month
• Has transjugular intrahepatic portosystemic shunt and/or has undergone portacaval shunting

Healthy Control Participants

• Has a history of clinically significant endocrine, gastrointestinal, cardiovascular, hematological, hepatic, immunological, renal, respiratory, genitourinary, or major neurological (including stroke and chronic seizures) abnormalities or diseases
• Is a regular user of cannabis products within approximately 6 months of study